Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Victor F. Tapson"'
Autor:
Nazzareno Galiè, Ioana R. Preston, Marius M. Hoeper, Lilla Di Scala, Lewis J. Rubin, G. Simonneau, Vallerie V. McLaughlin, Sean Gaine, Harrison W. Farber, Olivier Sitbon, Kelly Chin, Richard N. Channick, R Preiss, Victor F. Tapson, Irene M. Lang, Hossein Ardeschir Ghofrani
Publikováno v:
The Journal of Heart and Lung Transplantation. 37:401-408
Background: Parenteral prostacyclin analogs that target the prostacyclin pathway have been used to treat pulmonary arterial hypertension (PAH) since the 1990s. Abrupt discontinuation of parenteral prostacyclin analogs can be associated with acute det
Autor:
Erick Borg, Ricardo Restrepo, Pete Smith, Victor F. Tapson, Ashwin Ravichandran, Lisa D. Edwards, Aaron B. Waxman, Thenappan Thenappan, Steven D. Nathan
Publikováno v:
Chest. 158:A2179-A2180
Publikováno v:
JACC: Cardiovascular Interventions. 14:810
Publikováno v:
Journal of Cardiovascular Pharmacology. 67:322-325
Pulmonary arterial hypertension (PAH) has emerging therapeutic options including prostacyclin analogs. Inhaled therapy offers advantages compared with alternative routes of administration. We aimed to determine the safety and tolerability of inhaled
Autor:
Gisela Meyer, Robert Naeije, Victor F. Tapson, Milton Packer, Marius M. Hoeper, Rogério Souza, Hikmet Al Hiti, Hossein Ardeschir Ghofrani, Jonathan Tolson, Richard N. Channick, Vallerie V. McLaughlin, Jean Christophe Lemarié
Publikováno v:
European Respiratory Journal. 46:405-413
The safety and efficacy of adding bosentan to sildenafil in pulmonary arterial hypertension (PAH) patients was investigated.In this prospective, double-blind, event-driven trial, symptomatic PAH patients receiving stable sildenafil (≥20 mg three ti
Autor:
Harrison W. Farber, Lilla Di Scala, Irene Lang, Marius M. Hoeper, Lewis J. Rubin, Kelly Chin, Olivier Sitbon, Vallerie V. McLaughlin, Nazzareno Galiè, Ioana R. Preston, Hossein Ardeschir Ghofrani, Victor F. Tapson, Gérald Simonneau, R Preiss, Sean Gaine, Richard N. Channick
Publikováno v:
4.3 Pulmonary Circulation and Pulmonary Vascular Diseases.
Pulmonary arterial hypertension (PAH) patients (pts) treated with parenteral prostacyclins (PGI2) are at risk of developing rebound pulmonary hypertension or disease worsening upon abrupt treatment discontinuation. Less is known about the impact of i
Autor:
Jean Francois Marier, Victor F. Tapson, Kevin Laliberte, Carlos Jerjes, Tomás Pulido, David Yehle, Fernando Torres, Meredith Howell, R. James White, Roblee P Allen
Publikováno v:
Journal of Cardiovascular Pharmacology. 61:474-481
Pulmonary arterial hypertension (PAH) is a progressive vascular disease that ultimately leads to right ventricular failure and death. Treprostinil diolamine is an oral prostacyclin analogue; sustained release tablets of oral treprostinil are currentl
Autor:
Shelley M. Shapiro, Victor F. Tapson, Kevin Laliberte, Roblee P Allen, Robert P. Frantz, Anne Keogh, Carl Arneson, Fernando Torres, Jeffrey Sigman, David B. Badesch, Adaani E. Frost, Fiona Kermeen, Nazzareno Galiè
Publikováno v:
Chest. 142:1383-1390
Background Treprostinil is a stable prostacyclin analog approved for the treatment of pulmonary arterial hypertension (PAH) as parenteral or inhaled therapy. Treprostinil diolamine, a sustained-release oral formulation of treprostinil, was studied to
Autor:
Nazzareno Galiè, Hyuk Jae Chang, Hans Klose, Wei Yang, Deborah A. Quinn, Marius M. Hoeper, Andrew J. Peacock, Hiromi Matsubara, Robert P. Frantz, Victor F. Tapson, Yoshihiro Fukumoto, Carmine Dario Vizza, Robyn J. Barst, Michael Pfeifer, James M. Felser, Fernando Torres, Paul M. Hassoun, Adaani E. Frost, Hossein Ardeschir Ghofrani, Gérald Simonneau, Nicholas W. Morrell, David Lawrence
BACKGROUND: Imatinib is an oral inhibitor of several protein kinases implicated in the pathophysiology of pulmonary hypertension. Treatment with imatinib resulted in improved hemodynamics and exercise capacity in a controlled trial (Imatinib [QTI571]
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e04ef7dc162143472d3791133f1170bc
http://hdl.handle.net/11573/901480
http://hdl.handle.net/11573/901480
Autor:
Vallerie V. McLaughlin, David B. Badesch, Adaani E. Frost, Victor F. Tapson, Robyn J. Barst, Srinivas Murali, Henry H. Hsu, Lewis J. Rubin, Richard N. Channick, Ronald J. Oudiz
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 174:1257-1263
Small, open-label studies suggest that combinations of existing therapies may be effective for pulmonary arterial hypertension (PAH).To evaluate the safety and efficacy of adding inhaled iloprost, a prostacyclin analog, to the endothelin receptor ant